GlassScriptPhysician profile
Jennifer E Miller
NPI 1285111377
$1,756.30
in general payments reported to CMS, 2019-2025
23 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.43 · 2023: $138 · 2024: $520 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.33 | 2024-2025 | |
| Madrigal Pharmaceuticals | $208.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $127.53 | 2024-2025 | Entyvio, Eohilia |
| Baxter Healthcare | $112.91 | 2023 | Floseal |
| Pfizer INC. | $112.07 | 2024-2025 | |
| Qol Medical, LLC | $83.57 | 2025 | Sucraid |
| Ardelyx, INC. | $61.61 | 2024 | Ibsrela |
| Olympus America INC. | $50.57 | 2025 | Bovie, Uretero-Reno Videoscope |
| Sanofi-Aventis U.S. LLC | $48.69 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $44.82 | 2024 | Dupixent |
| Sanofi Pasteur INC. | $44.26 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.85 | 2024-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $41.04 | 2024-2025 | Vowst |
| Alnylam Pharmaceuticals INC. | $37.92 | 2024-2025 | Givlaari |
| Phathom Pharmaceuticals, INC. | $26.82 | 2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $25.00 | 2023 | Flumist Quadrivalent |
| Gilead Sciences, INC. | $24.69 | 2025 | |
| Genzyme Corporation | $24.39 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $23.27 | 2024 | Iqirvo |
| Kci USA, INC. | $20.17 | 2022 | |
| Evoke Pharma, INC. | $20.14 | 2025 | |
| Braintree Laboratories, INC. | $20.08 | 2025 | Suflave |
| Merck Sharp & Dohme LLC | $19.72 | 2024 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.